Synthesis, characterization and in vitro inhibition of metal complexes of pyrazole based sulfonamide on human erythrocyte carbonic anhydrase isozymes I and II

Nurgün Büyük İskinden, Bülent Büyük İskinden, Metin Bülbül, Rahmi Kasımoğulları and Samet Mert

Department of Chemistry, Arts and Science Faculty, Dumlupınar University, Kutahya, Turkey

ABSTRACT
Sulfonamides represent an important class of biologically active compounds. A sulfonamide possessing carbonic anhydrase (CA) inhibitory properties obtained from a pyrazole based sulfonamide, ethyl 1-(3-nitrophenyl)-5-phenyl-3-(5-sulfamoyl-1,3,4-thiadiazole-2-yl)carbamoyl-1H-pyrazole-4-carboxylate (1), and its metal complexes with the Ni(II) for (2), Cu(II) for (3) and Zn(II) for (4) have been synthesized. The structures of metal complexes (2–4) were established on the basis of their elemental analysis, 1H NMR, IR, UV–Vis and MS spectral data. The inhibition of two human carbonic anhydrase (hCA, EC 4.2.1.1) isoenzymes I and II, with 1 and synthesized complexes (2–4) and acetazolamide (AAZ) as a control compound was investigated in vitro by using the hydratase and esterase assays. The complexes 2, 3 and 4 showed inhibition constant in the range 0.1460–0.3930 μM for hCA-I and 0.0740–0.0980 μM for hCA-II, and they had effective more inhibitory activity on hCA-I and hCA-II than corresponding free ligand 1 and than AAZ.

Introduction
Sulfonamides represent a significant class of biologically active compounds that inhibit carbonic anhydrase (CA, EC 4.2.1.1) isoenzymes involved in different pathological and physiological events. Carbonic anhydrases are a super family of metallo enzymes that catalyze the interconversion of carbondioxide (CO₂) and water (H₂O) to bicarbonate (HCO₃⁻) and protons (H⁺)1–6.

The α-CA is the best known group in the six genetically distinct CA families (α, β, γ, δ, ζ, and η)7–13. A total of 16 isoenzymes have been previously described as members of the α-CA family, and classified according to their subcellular localization. CAs I, II, III, VII and XIII are cytosolic isoenzymes14–16. CAs VA and VB are localized in the mitochondria17–19. CA VI is a unique secreted isoenzyme18,19. CAs IX, XII and XIV are transmembrane proteins20,21 and CAs IV and XV are GPI-anchored to the cell membrane.22

1,3,4-Thiadiazole-2-sulfonamide derivatives23–28 played a critical role in the development of several important classes of pharmacological agents, such as the diuretics with saluretic action,29,30 benzothiadiazine31 and high-ceiling diuretics,32 or the antiglaucoma drugs with CA inhibitory action, among others.33,34

The coordination chemistry of pyrazoles and other heterocyclic compounds containing nitrogen has attracted much attention because of their interesting structural properties and application in diverse areas.35 The ease of synthesis of various substituted pyrazoles is the most interesting feature in the incorporation of pyrazole groups in the design of new ligands and offers the opportunity of both electronic and steric control of the properties of the metal complexes.

Generally, metal complexes of heterocyclic sulfonamides are 10–100 times more active as CA inhibitors than the sulfonamides from which they were obtained, assuring affinities for the receptor in the 10¹⁰ to 10¹² range.36–41

Recently, we have reported the metal complexes of some pyrazole-based 1,3,4-thiadiazole-2-sulfonamides show very strong CA inhibitory properties.42,43

In this work, three new air stable complexes 2, 3 and 4 have been reported, and they can be seen as candidates for further in vivo studies for the treatment of glaucoma which were synthesized by the reaction of M(II) (Ni(II) (2), Cu(II) (3) and Zn(II) (4)) with 1 (Figure 1). The newly obtained complexes 2, 3 and 4 were characterized by standard procedures in order to assign their structures, and were assayed as CA inhibitors against hCA-I and hCA-II isoenzymes.

Materials and methods
All reagents were the highest grade commercially available and used without further purification. Compound 1 was synthesised by literature method.44 1H NMR spectrum was recorded with a Bruker DPX FT NMR (500 MHz) spectrometer (Billerica, MA). Elemental analyses for C, H, N and S were performed on a Leco CHNS-932 instrument (St Joseph, MI). MS spectra of the complexes were recorded using by Varian Mat III 80 eV (Palo Alto, CA). IR spectra were recorded on a Bruker Optics, vertex 70 FT-IR spectrometer using ATR techniques. The UV–vis spectra were carried out with a Shimadzu UV-2550 spectrometer (Kyoto, Japan) in the range 900–200 nm. Magnetic susceptibility measurements at room temperature were taken using a Sherwood Scientific Magway MSB MK1 model (Cambridge, UK).
magnetic balance by the Gouy method using Hg[Co(SCN)4] as calibrant.

**General procedure for synthesis of 2, 3 and 4**

A solution of MX2·nH2O (NiCl2·6H2O for (2), CuCl2·2H2O for (3) and Zn(NO3)2·4H2O for (4)) (2.20 × 10−4 mol) in 10 mL ethanol was added dropwise with continuous stirring to 20 mL of an ethanolic solution containing 1 (1.1 × 10−4 mol). The pH of the reaction mixture was adjusted by addition of 0.1 M aqueous NaOH solution in the range between 6.0 and 7.0. The reaction mixture was stirred overnight at room temperature to give an air stable solid of titled complexes 2, 3 and 4.

**Synthesis of 2:** Blue solid, 67% yield, m.p. 238°C (decompose); IR (cm−1): 3504 (OH), 3390 and 3235 (NH2), 3074 (CH)ar., 2985 and 2928 (CH)aliph., 1724 (ester C=O), 1624 (amide C=O), 1534, 1489 (Ar C= C/C=N), 1173 (SO2), 589 (Cu–O) and 472 (Cu–N).

**UV–Vis:** [λ (nm), εmax (L mol−1 cm−1)]; 290 (36 130), 301 (43 400), 304 (43 400) (π–π*), 784 (120) (d–d).

MS: m/z 1142.9 [NiC21H17N7O7S2]+, 498.0 [C21H17N7O7S2]+, 949.0 [C21H17N7O7S2]+, 79.1 [H2NO2S]+.

C21H17N7O7S2: Anal. calc (%): C, 42.76; H, 3.08; N, 16.62; S, 10.73.

**Synthesis of 3:** Green solid, 78% yield, m.p. 224°C (decompose); IR (cm−1): 3600 (OH), 3412 and 3283 (NH2), 3098 (CH)ar., 2984 and 2928 (CH)aliph., 1729 (ester C=O), 1624 (amide C=O), 1534, 1489 (Ar C= C/C=N), 1172 (SO2), 589 (Cu–O) and 472 (Cu–N).

**UV–Vis:** [λ (nm), εmax (L mol−1 cm−1)]; 290 (36 700), 301 (43 400) (π–π*), 780 (250) (d–d).

MS: m/z 1147.7 [CuC21H17N7O7S2]+, 544.0 [C21H17N7O7S2]+, 497.9 [C21H17N7O7S2]+, 79.2 [H2NO2S]+.

C21H17N7O7S2: Anal. calc (%): C, 42.58; H, 3.06; N, 16.55; S, 10.83. Found (%): C, 42.65; H, 3.11; N, 16.62; S, 10.71.

**Synthesis of 4:** White solid, 54% yield, m.p. 239°C (decompose); 1H NMR (500 MHz, DMSO-d6): δ 8.06 (s, 4H, SO2NH2), 7.99–7.25 (m, 18H, ArH), 4.11 (s, 4H, CH2), 1.07 (s, 4H, H2O), 1.05 (m, 6H, CH3), IR (cm−1): 3441 (OH), 3397 and 3268 (NH2), 3074 (CH)ar., 2985 and 2928 (CH)aliph., 1727 (ester C=O), 1624 (amide C=O), 1549, 1473 (Ar C= C/C=N), 1172 (SO2), 586 (Zn–O) and 478 (Zn–N).

**UV–Vis:** [λ (nm), εmax (L mol−1 cm−1)]; 282 (16 260), 323 (10 180) (π–π*). MS: m/z 1148.8 [ZnC21H17N7O7S2]+, 543.9 [C21H17N7O7S2]+, 498.0 [C21H17N7O7S2]+, 79.2 [H2NO2S]+.

C21H17N7O7S2: Anal. calc (%): C, 42.52; H, 3.06; N, 16.53; S, 10.81. Found (%): C, 43.73; H, 2.86; N, 17.35; S, 11.32.

---

**Purification of isoenzymes hCA-I and hCA-II from human erythrocytes**

In order to purify hCA-I and hCA-II isoenzymes, first, human blood was centrifuged at 1500 rpm for 20 min, and after the removal of the plasma, the erythrocytes were washed with an isotonic solution (0.9% NaCl). After that, the erythrocytes were lysed with 1.5 volume of ice-cold water. The lysate was centrifuged at 20 000 rpm for 30 min to remove cell membranes and non-lysed cells. The pH of the supernatant was adjusted to 8.7 with tris and was then loaded onto an affinity column containing Sepharose-4B-L-tyrosine-p-aminobenzene sulfonamide as the binding group. After extensive washing with 25 mM tris–HCl/22 mM Na2SO4 (pH 8.7), the hCA-I and hCA-II isoenzymes were eluted with 1.0 M NaCl/25 mM NaHPO4 (pH 6.3) and 0.1 M CH4COONa/0.5 M NaClO4 (pH 5.6). The amount of purified protein was estimated by the Bradford method and SDS-PAGE was carried out to determine whether the elute containing the enzyme (Supplemental Figure 1).

---

**Carbonic anhydrase assay**

Carbonic anhydrase was assayed by following the hydration of CO2 according to the method described by Wilbur and Anderson. CO2-hydratase activity as an enzyme unit (EU) was calculated by using the equation (t0–t1)/t2 where t0 and t1 are the times for pH change of the nonenzymatic and the enzymatic reactions, respectively. IC50 values (the concentration of inhibitor producing a 50% inhibition of CA activity) have been obtained as in vitro for the free ligand (1), newly synthesized compounds (2–4) and AAZ as the control compound.

---

**Esterase activity assay**

Carbonic anhydrase activity was assayed by following the change in absorbance at 348 nm of 4-nitrophenylacetate (NPA) to 4-nitrophenylate ion over a period of 3 min at 25°C using a spectrophotometer (CHEBIOS UV-Vis, Roma, Italy) according to the method described in the literature. The enzymatic reaction, in a total volume of 3.0 mL, contained 1.4 mL of 0.05 M tris–SO4 buffer (pH 7.4), 1 mL of 3 mM 4-nitrophenylacetate, 0.5 mL H2O and 0.1 mL enzyme solution. A reference measurement was obtained by preparing the same cuvette without enzyme solution. IC50 values have been obtained as in vitro for free ligand (1), the novel synthesized compounds (2–4) and AAZ as the control compound.

---

**Figure 1.** Syntheses of complexes 2, 3 and 4.
Table 1. IR spectral data (cm⁻¹) of the free ligand (1) and complexes 2, 3 and 4.

| Assignments | 1 | 2 | 3 | 4 |
|-------------|---|---|---|---|
| ν(OH)        | – | 3504 (br) | 3600 (br) | 3441 (br) |
| ν(NH₂)       | – | 3390 (w) | 3412 (w) | 3397 (w) |
| ν(NH₂)       | 3227 (w) | 3235 (w) | 3241 (w) | 3276 (w) |
| ν(C–H)       | 3094 (w) | 3098 (w) | 3094 (w) | 3074 (w) |
| ν(C=O)       | 1738 (s) | 1726 (s) | 1729 (s) | 1727 (s) |
| ν(C=O)amide  | 1659 (s) | 1617 (s) | 1624 (s) | 1606 (s) |
| ν(C=C=C–N)   | 1523, 1478, 1431 (m) | 1536, 1491 (m) | 1534, 1489 (m) | 1549, 1473 (m) |
| ν(SO₂)       | 1165 (m) | 1172 (m) | 1173 (m) | 1172 (m) |
| ν(M–O)       | – | 591 (m) | 589 (m) | 586 (m) |
| ν(M–N)       | – | 484 (m) | 472 (m) | 478 (m) |

w: weak; br: broad; m: medium; s: strong.

Determination of Kᵢ values

The method for determination of Kᵢ values is described elsewhere. In the first part of this study, IC₅₀ values have been obtained as in vitro. IC₅₀ of the free ligand (1), synthesized complexes (2–4) and AAZ as the control compound were assayed by the hydrolysis of p-nitrophenylacetate on esterase activities of CA isozymes in the presence of various inhibitor concentrations. The absorbance was determined at 348 nm after 3 min. Regression analysis graphs were drawn by plotting inhibitor concentrations versus enzyme activity by using Microsoft Excel Program.

In the second part of the study, enzyme activity was measured in the presence of five different substrate concentrations at each of these inhibitor concentrations (30%, 50% and 70%), and the data were linearized with Lineweaver–Burk plot in order to obtain Kᵢ values.

¹H NMR spectrum of Zn(II) complex (4)

Due to its diamagnetic nature, the Zn(II) complex (4) was studied by NMR spectroscopy and its ¹H NMR spectrum is given in Supplemental Figure 2. The comparison of the ¹H NMR spectrum of the complex (4) with the spectrum of free ligand gave valuable information regarding the coordination mode of ligand during complexation. The peak corresponds to CONH proton found in the spectrum of free ligand at 7.25 ppm which is shifted to 7.99 ppm indicating that the deprotonated CONH group of SO₂NH₂ protons give a signal at 8.32 ppm which is shifted to 8.11 ppm for the complex (4) of the free ligand (1) in the complexes (2–4) and AAZ as the control compound were assayed by the hydrolysis of p-nitrophenylacetate on esterase activities of CA isozymes in the presence of various inhibitor concentrations. The absorbance was determined at 348 nm after 3 min. Regression analysis graphs were drawn by plotting inhibitor concentrations versus enzyme activity by using Microsoft Excel Program.

In the second part of the study, enzyme activity was measured in the presence of five different substrate concentrations at each of these inhibitor concentrations (30%, 50% and 70%), and the data were linearized with Lineweaver–Burk plot in order to obtain Kᵢ values.

¹H NMR spectrum of Zn(II) complex (4)

Due to its diamagnetic nature, the Zn(II) complex (4) was studied by NMR spectroscopy and its ¹H NMR spectrum is given in Supplemental Figure 2. The comparison of the ¹H NMR spectrum of the complex (4) with the spectrum of free ligand gave valuable information regarding the coordination mode of ligand during complexation. The peak corresponds to CONH proton found in the spectrum of free ligand at 7.25 ppm which is shifted to 7.99 ppm indicating that the deprotonated CONH group of SO₂NH₂ protons give a signal at 8.32 ppm which is shifted to 8.11 ppm for the complex (4) of the free ligand (1) in the complexes (2–4) and AAZ as the control compound were assayed by the hydrolysis of p-nitrophenylacetate on esterase activities of CA isozymes in the presence of various inhibitor concentrations. The absorbance was determined at 348 nm after 3 min. Regression analysis graphs were drawn by plotting inhibitor concentrations versus enzyme activity by using Microsoft Excel Program.

In the second part of the study, enzyme activity was measured in the presence of five different substrate concentrations at each of these inhibitor concentrations (30%, 50% and 70%), and the data were linearized with Lineweaver–Burk plot in order to obtain Kᵢ values.

FT-IR measurements

The significant frequencies in the IR spectra of the free ligand (1) and the complexes (2–4) are given in Table 1. The broad absorption bands at 3504, 3600 and 3441 cm⁻¹ are attributed to (O–H) of water in compounds 2, 3 and 4 respectively. Two stretching frequencies were obtained for the asymmetric (3390 cm⁻¹) and symmetric (3235 cm⁻¹) vibrations of the sulfonamido NH₂ moiety for compound 2. These asymmetric and symmetric bands were observed at 3412 and 3241 cm⁻¹, respectively, for compound 3 and at 3397 and 3276 cm⁻¹, respectively, for compound 4.

The N–H stretching vibration was observed at 3227 cm⁻¹ for 1. The band corresponding to the amide ν(C=O) vibration of the pyrazole carboxamide (1659 cm⁻¹) of 1 is observed as a single band shifted to lower frequencies (about 1624–1606 cm⁻¹) in the complexes (2–4). This fact could be attributed to the bonding of the metal ions with the amide nitrogen of the ligand. Absorptions at 1523, 1478 and 1431 cm⁻¹ assigned to the ν(C=C=C–N) vibrations of 1 are slightly shifted from those found in 2 (1536 and 1491 cm⁻¹), 3 (1534, 1489 cm⁻¹) and 4 (1549, 1473 cm⁻¹). These data of complexes 2, 3 and 4 are also attributed to the coordination occurring from nitrogen atom of pyrazole ring of 1. Weak bands at 591 and 484 cm⁻¹ for 2, 589 and 472 cm⁻¹ for 3 and 586 and 478 cm⁻¹ for 4 are corresponded with M–O and M–N vibrations, respectively.

UV/vis spectra and magnetic susceptibility

The electronic spectra of compounds 1–4 were recorded in DMSO solutions at a 1 × 10⁻³ M concentration at room temperature (Table 2). The electronic spectrum of 2 exhibits three intense absorption bands at 290, 301 and 304 nm that were assigned to π–π* and the broad absorption band at 784 nm was assigned to d–d transitions of a 6-coordinate octahedral geometry. Two bands for compound 3 (290 and 301 nm) were assigned to π–π* transitions similarly to other sulfonamide derivatives containing 1,3,4-thiadiazole-2-sulfonamide ring. In addition, the electronic spectrum of 3 also exhibiting a broad band at 780 nm is attributable to d–d transition. The Zn(II) complex (4) did not show any d–d transition and its spectrum was dominated only by the π–π* transition bands at 282 and 323 nm. The magnetic susceptibility measurements were carried out on powdered samples at room temperature. The magnetic moment value for Ni(II) complex (2) is 3.64 B.M. which is in good agreement with a d⁸ system in an octahedral environment. The magnetic moments of the complexes at room temperature lie in the range of 3.53–4.26 B.M. for mono nuclear octahedral Ni(II) centers. The measured magnetic moment of 3 is 1.87 B.M. which is consistent with the expected spin-only magnetic moment of d⁸ Cu(II) systems. The spectral data and magnetic moment value indicate an octahedral geometry around Cu(II) ion. As expected, the room temperature magnetic moment value of Zn(II) complex (4) is found to be diamagnetic due to non-availability of unpaired electrons.

MS spectral studies of 2, 3 and 4

The MS spectra give additional structural information about the chemical structure of the studied complexes 2, 3 and 4. None of the MS spectra of complexes showed a molecular ion [M]+ peak. The fragment [MC₄H₃₂N₁₄O₁₄S₄]⁺ which suggests the monomeric nature of the complexes is observed at m/z 1142.9 for 2 and
1147.7 for 3 and 1148.8 for 4. The fragment [C₂|H₂|N₂O₂S₂]⁺ is observed at m/z 544.0 for 2 and for 3 and 543.9 for 4. The peaks are observed at m/z 498.0 and 79.1 for 2, 497.9 and 79.2 for 3, and 498.0 and 79.2 for 4 which are due to the fragment [C₂|H₂|N₂O₂S₂]⁺ and [H₂|N₂O₂S₂]⁺, respectively. These data confirmed the proposed formula of the complexes (Figure 1).

**In vitro inhibition studies**

Inhibition effects on hCA-I and hCA-II isoenzymes of the newly synthesized compounds (2-4) and acetazolamide (AAZ) as a control compound were studied by hydratase and esterase activity methods and \( K_i \) values were determined for each compound and compared to inhibition effect of the free ligand (1) (Table 3).

According to the in vitro studies, the \( IC_{50} \) values of hydratase activities of newly synthesized compounds 3 and 4 (0.0600 and 0.0520 \( \mu \)M for hCA-I and 0.0340 and 0.0420 \( \mu \)M for hCA-II, respectively) are lower than the \( IC_{50} \) values of 1 (1.4000 and 0.9000 \( \mu \)M for hCA-I and hCA-II, respectively) and of AAZ (3.3000 and 2.4000 \( \mu \)M for hCA-I and II, respectively). The \( IC_{50} \) values of hydratase activities of 2 2.4000 \( \mu \)M for hCA-I is lower than AAZ but higher than 1 and 0.0625 \( \mu \)M for hCA-II lower than both 1 and AAZ. The \( IC_{50} \) values of esterase activities of compounds 2, 3 and 4 (0.0820, 0.1450 and 0.3400 \( \mu \)M for hCA-I and 0.0190, 0.0900 and 0.0920 for hCA-II) are all lower than the \( IC_{50} \) values of esterase activities for free ligand (1) (2.8000 and 5.6000 \( \mu \)M for hCA-I and hCA-II, respectively) and AAZ (4.6000 and 3.9000 \( \mu \)M for hCA-II, respectively).

In relation to the esterase activities, the inhibition equilibrium constants (\( K_i \)) were also determined. The pyrazole carboxamide group of 1 forms a hydrogen bond with the histidine residue in the active site of CA to inhibit the isozymes (\( K_i \): 1.1000 and 5.3000 \( \mu \)M for hCA-I and hCA-II, respectively), resulting in less movement of the carbonic acid toward \( CO_2 \) production.63 The coordination compounds (2, 3 and 4) show remarkable inhibition on hCA-I and hCA-II (\( K_i \): 0.1460, 0.1480 and 0.3930 \( \mu \)M and 0.0960, 0.0724 and 0.0980 \( \mu \)M, respectively), having a higher inhibition as compared to 1 as well as to the control compound AAZ (2.8000 and 2.1000 \( \mu \)M for hCA I and hCA-II, respectively), which is probably due to complexation of metal(II) ions to ligand.64

In summary, these new compounds (2-4) have quite a lot higher potential inhibitory effects than their parent inhibitors 1 and AAZ. Thus, the complexes (2-4) might be good candidates for further clinical studies of glaucoma treatment. Especially, compounds 3 and 4 have shown remarkable inhibition against hCA-II and hCA-I isoenzymes for hydratase activities, and compound 2 has shown remarkable inhibition against hCA-I and hCA-II isoenzymes for esterase activities. The order of the metal ions for the inhibition of hCA-I for hydratase activity is \( Zn > Cu > Ni \), and of hCA-I for esterase activity is \( Ni > Cu > Zn \), and of hCA-II for hydratase activity is \( Cu > Zn > Ni \), and of hCA-II for esterase activity is \( Ni > Cu > Zn \).

**Disclosure statement**

The authors report no declarations of interest.

**Funding**

This work was supported by Scientific and Technological Research Council of Turkey (TÜBİTAK) with Grant No. TBAG-104T406.

**References**

1. Gülçin İ, Beydemir Ş. Büyükkokuroğlu ME. In vitro and in vivo effects of dantrolene on carbonic anhydrase enzyme activities. Biol Pharm Bull 2004;27:613–16.

2. Beydemir Ş, Gülçin I. Effects of melatonin on carbonic anhydrase from human erythrocytes in vitro and from rat erythrocytes in vivo. J Enzyme Inhib Med Chem 2004;19:193–7.

3. Aras-Hisar Ş, Hisar O, Beydemir Ş, et al. Effect of vitamin E on carbonic anhydrase enzyme activity in rainbow trout (Oncorhynchus mykiss) erythrocytes in vitro and in vivo. Acta Vet Hung 2004;52:413–22.

4. Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767–77.

5. Marini AM, Maresca A, Aggarwal M, et al. Tricyclic sulfonamides incorporating benzothiopyran[4,3-c]pyrazole and pyridothio.pyran[4,3-c]pyrazole effectively inhibit \( \alpha \)- and \( \beta \)-carbonic anhydrase: X-ray crystallography and solution investigations on 15 isoforms. J Med Chem 2012;55:9619–29.

6. Topal M, Gülçin I. Rosmarinic acid: a potent carbonic anhydrase isoenzymes inhibitor. Turk J Chem 2013;38:894–902.

7. Zimmerman SA, Ferry JG, Supuran CT. Inhibition of the archael beta-class (Cab) and gamma-class (Cam) carbonic anhydrases. Curr Top Med Chem 2007;7:901–18.

8. Çetinkaya Y, Göçer H, Gülçin İ, Menzek A. Synthesis and carbonic anhydrase isoenzymes inhibitory effects of brominated diphenylmethane and its derivatives. Arch Pharm 2014;347:354–9.

9. Çetinkaya Y, Göçer H, Göküs S, Gülçin I. Synthesis and carbonic anhydrase isoenzymes I and II inhibitory effects of novel benzylamine derivatives. J Enzyme Inhib Med Chem 2014;29:168–74.

10. Güney M, Coşkun A, Topal F, et al. Oxidation of cyanobenzo-cycloheptatrienes: synthesis, photoxyogenation reaction and carbonic anhydrase isoenzymes inhibition properties of some new benzotropone derivatives. Bioorg Med Chem 2014;22:3537–43.

11. Nar M, Çetinkaya Y, Gülçin İ, Menzek A. (3,4-Dihydroxyphenyl)(2,3,4-trihydroxyphenyl)methane and its derivatives as carbonic anhydrase isoenzymes inhibitors. J Enzyme Inhib Med Chem 2013;28:402–6.

**Table 2.** Optical properties of compounds 1-4 in dimethylsulfoxide.

|   | \( \lambda_{	ext{max}} \) (nm) (\( \varepsilon \) (L mol⁻¹ cm⁻¹)) |
|---|---|
|   | 1 | 2 | 3 | 4 |
| DMSO | 290 (34 750) | 290 (36 130) | 290 (36 700) | 282 (16 260) |
|     | 296 (40 390) | 301 (43 400) | 301 (43 400) | 323 (10 180) |
|     | 304 (43 400) | 780 (250) | 784 (120) |

**Table 3.** \( IC_{50} \) values of AAZ and 1-4 on hydratase and esterase activity of hCA-I and hCA-II and \( K_i \) values of hCA-I and hCA-II.

| Inhibitor | Hydratase \( IC_{50} \) (\( \mu \)M) | Esterase \( IC_{50} \) (\( \mu \)M) | \( K_i \) (\( \mu \)M) |
|---|---|---|---|
| AAZ | 3.3000 | 2.8000 | 3.9000 | 2.8000 | 2.1000 |
| 1 | 3.3000 | 0.9000 | 2.8000 | 5.6000 | 1.1000 | 5.3000 |
| 2 | 2.4000 | 0.0625 | 0.0820 | 0.0190 | 0.1460 | 0.0960 |
| 3 | 0.0600 | 0.0340 | 0.1450 | 0.0900 | 0.1480 | 0.0724 |
| 4 | 0.0520 | 0.0420 | 0.3400 | 0.0920 | 0.3930 | 0.0980 |
12. Hisar O, Beydemir S, Gülcin İ, et al. Effects of low molecular weight plasma inhibitors of rainbow trout (Oncorhynchus mykiss) on human erythrocyte carbonic anhydrase-II isozyme activity in vitro and rat erythrocytes in vivo. J Enzyme Inhib Med Chem 2005;20:35–9.

13. Akincıoğlu A, Topal M, Gülcin İ, Göksu S. Novel sulphamides and sulphonamides incorporating the tetralin scaffold as carbonic anhydrase and acetylcholine esterase inhibitors. Arch Pharm (Weinheim) 2014;347:68–76.

14. Sly WS, Hu PY. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem 1994:29–41.

15. Montgomery JC, Venta PJ, Eddy RL, et al. Characterization of the human gene for a newly discovered carbonic anhydrase, CA VII, and its localization to chromosome 16. Genomics 1999;11:835–48.

16. Lehtonen J, Shen B, Vihinen M, et al. Characterization of CA XII, a novel member of the carbonic anhydrase isozyme family. J Biol Chem 2004;279:2719–27.

17. Fujikawa-Adachi K, Nishimori I, Taguchi T, Onishi S. Human mitochondrial carbonic anhydrase VB. cDNA cloning, mRNA expression, subcellular localization, and mapping to chromosome x. J Biol Chem 1999;274:21228–33.

18. Murakami H, Sly WS. Purification and characterization of human salivary carbonic anhydrase. J Biol Chem 1987;262:1382–8.

19. Aksu K, Nar M, Tanç M, et al. Synthesis and carbonic anhydrase inhibitory properties of sulfamides structurally related to dopamine. Bioorg Med Chem 2013;21:2925–31.

20. Tureci O, Sahin U, Vollmar E, et al. Human carbonic anhydrase XII: cDNA cloning, mRNA expression, subcellular localization, and mapping to chromosome 18. J Biol Chem 1999;274:21228–33.

21. Fujikawa-Adachi K, Nishimori I, Taguchi T, Onishi S. Human carbonic anhydrase XIV (CA14): cDNA cloning, mRNA expression, and mapping to chromosome 1. Genomics 1999;61:74–81.

22. Zhu XL, Sly WS. Carbonic anhydrase IV from human lung. Purification, characterization, and comparison with membrane carbonic anhydrase from human kidney. J Biol Chem 1990;265:8795–801.

23. Roblin RO, Clapp JW. The preparation of heterocyclic sulfonamides. J Am Chem Soc 1950;72:4890–2.

24. Miller WH, Dessert AM, Roblin RO. Heterocyclic sulfonamides as carbonic anhydrase inhibitors. J Am Chem Soc 1950;72:4893–6.

25. Vaughan JR, Eichler JA, Anderson GW. Notes – heterocyclic sulfonamides as carbonic anhydrase inhibitors. 2-Acylamido- and 2-sulfonylamido-1,3,4-thiadiazole-5-sulfonamides. J Org Chem 1956;21:700–1.

26. Young RW, Wood KH, Vaughan JR, Anderson GW. 1,3,4-Thiadiazole- and thiadiazolinesulfonamides as carbonic anhydrase inhibitors. Synthesis and structural studies. J Am Chem Soc 1956;78:4649–54.

27. Mert S, Alım Z, İsgör MM, et al. The synthesis of novel pyrazole-3,4-dicarboxamides bearing 5-amino-1,3,4-thiadiazole-2-sulfonamide moiety with effective inhibitory activity against the isoforms of human cytosolic carbonic anhydrase I and II. Bioorg Chem 2016;68:664–71.

28. Supuran CT, Carbonic anhydrase inhibitors. In: Puscas I, ed. Carbonic anhydrase and modulation of physiologic and pathologic processes in the organism. Timisoara: Helicon; 1994:29–111.

29. Maren TH. Carbonic anhydrase: chemistry, physiology, and inhibition. Physiol Rev 1967;47:595–781.

30. Supuran CT, Conroy CW, Maren TH. Carbonic anhydrase inhibitors: synthesis and inhibitory properties of 1,3,4-thiadiazole-2,5-bisulfonamide. Eur J Med Chem 1996;31:843–6.

31. Bayer KH, Baer JE. Physiological basis for the action of newer diuretic agents. Pharmacol Rev 1961;13:517–62.

32. Maren TH. Relations between structure and biological activity of sulfonamides. Annu Rev Pharmacol Toxicol 1976;16:309–27.

33. Mincone F, Menabuoni L, Briganti F, et al. Carbonic anhydrase inhibitors: inhibition of isozymes I, II and IV with N-hydroxysulfonamides – a novel class of intraocular pressure lowering agents. J Enzyme Inhib 1998;13:267–84.

34. Sugrue MF. The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. J Ocul Pharmacol Ther 1996;12:363–76.

35. Jadeja RN, Shah JR, Suresh E, Paul P. Synthesis and structural characterization of some Schiff bases derived from 4-[[(aryl)iminomethyl]-3-methyl-1-(4’-methylphenyl)-2-pyrazolin-5-one and spectroscopic studies of their Cu(II) complexes. Polyhedron 2004;23:2465–74.

36. Sumalan SL, Casanova J, Alzuet G, et al. Synthesis and characterization of metal(II)-8-quinolinolsulfonamidato (sa-) complexes (M = Co, Ni, Cu, and Zn). Crystal structure of [Zn(sa)2(NH3)2] complex. Carbonic anhydrase inhibitory properties. J Inorg Biochem 1996;62:31–9.

37. Supuran CT. Thiophenothiopyransulfonamides as complexing agents for the preparation of dual carbonic inhibitors. Met Based Drugs 1995;2:327–30.

38. Borras V, Cristea T, Supuran CT. Complexes with biologically active ligands. Part 5. Zn(II) and Cd(II) coordination compounds of hydrazine and heterocyclic sulfonamides as inhibitors of the zinc enzyme carbonic anhydrase. Main Group Met Chem 1996;19:339–410.

39. Minicone G, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Part 46. Inhibition of carbonic anhydrase isozymes I, II and IV with trifluoromethylsulfonamide derivatives and their zinc(II) and copper(II) complexes. Met Based Drugs 1997;4:27–34.

40. Borrás J, Casanova J, Cristea T, et al. Complexes with biologically active ligands. Part 6. Ni(II) coordination compounds of hydrazine and heterocyclic sulfonamides as inhibitors of the zinc enzyme carbonic anhydrase. Met Based Drugs 1996;3:143–8.

41. Scozzafava A, Supuran CT. Complexes with biologically active ligands. Part 10. Inhibition of carbonic anhydrase isozymes I and II with metal complexes of imidazolo[2,1-b]:1,3,4-thiadiazole-2 sulfonamide. Met Based Drugs 1997;4:19–26.

42. Büyükkidın N, Büyükıdın B, Bülbül M, et al. Synthesis and characterisation of novel Co(II) complexes of pyrazole carboxylate derived of sulfonamide as carbonic anhydrase inhibitors. J Pharm Pharmacol 2013;65:363–9.

43. Büyükıdın N, Bülbül M, Kasimoğulları R, Büyükıdın B. Synthesis and characterization of metal complexes of heterocyclic sulfonamide as carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2013;28:311–15.

44. Bülbül M, Kasimoğulları R, Küfrevioğlu O. Amide derivatives with pyrazole carboxylic acids of 5-amino-1,3,4-thiadiazole-2-sulfonamide as new carbonic anhydrase inhibitors: synthesis and investigation of inhibitory effects. J Enzyme Inhib Med Chem 2008;23:895–900.
45. Arslan B, Nalbantoglu B, Demir N, et al. A new method for the purification of carbonic anhydrase isozymes by affinity chromatography. Trop J Med Sci 1996;26:163–6.

46. Rickli EE, Ghazanfar SA, Gibbson BH, Edsall JT. Carbonic anhydrases from human erythrocytes. Preparation and properties of two enzymes. J Biol Chem 1964;239:1065–78.

47. Bradford MM. Determination of sepharose-bound protein with Coomassie brilliant blue G-250. Anal Biochem 1985;151:571–4.

48. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680–5.

49. Wilbur KM, Anderson NG. Electrometric and colorimetric determination of carbonic anhydrase. J Biol Chem 1948;176:147–54.

50. Verpoorte JA, Mehta S, Edsall JT. Esterase activities of human carbonic anhydrases B and C. J Biol Chem 1967;242:4221–9.

51. Innocenti A, Scozzafava A, Parkkila S, et al. Investigations of the esterase, phosphatase, and sulfatase activities of the cytosolic mammalian carbonic anhydrase isozymes I, II, and XIII with 4-nitrophenyl esters as substrates. Bioorg Med Chem Lett 2008;18:2267–71.

52. Landolfi C, Marchetti M, Ciocci G, Milanese C. Development and pharmacological characterization of a modified procedure for the measurement of carbonic anhydrase activity. PharmacoI Toxicol Methods 1997;38:169–72.

53. Bülbül M, Hisar O, Beydemir Ş, et al. The in vitro and in vivo inhibitory effects of some sulfonamide derivatives on rainbow trout (Oncorhynchus mykiss) erythrocyte carbonic anhydrase activity. J Enzyme Inhib Med Chem 2003;18:371–5.

54. Ciftci M, Bülbül M, Gül M, et al. Effects of nicotine and vitamin E on carbonic anhydrase activity in some rat tissues in vivo and in vitro. J Enzyme Inhib Med Chem 2005;20:103–8.

55. Hisar O, Beydemir Ş, Bülbül M, Yanik T. Kinetik properties of carbonic anhydrase purified from gills of rainbow trout (Oncorhynchus mykiss). J Appl Anim Res 2006;30:185–8.

56. Winum JY, Cecchi A, Montero JL, et al. Carbonic anhydrase inhibitors. Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with boron-containing sulfonamides, sulfamides, and sulfamates: toward agents for boron neutron capture therapy of hypoxic tumors. Bioorg Med Chem Lett 2005;15:3302–6.

57. Pedregosa JC, Casanova J, Aluet G, et al. Metal complexes of 5-tertbutyloxycarbonylamido-1,3,4-thiadiazole-2-sulfonamide (B-H2ats), a carbonic anhydrase inhibitor. Synthesis and characterization of the copper(II) complex. Crystal structures of B-H2ats and the [Cu(B-ats)(NH3)2]2 dimer complex. Inorg Chim Acta 1995;123:117–24.

58. Barros-Garcia FJ, Bernalte-Garcia A, Luna-Giles F, et al. Synthesis, characterization and crystal structures of bidentate indazole-thiazine derivative ligand and its cobalt(II) and cadmium (II) metal complexes. Polyhedron 2006;25:52–60.

59. Krillova MV, Da Silva MF CG, Kirillov AM, et al. 3D hydrogen bonded heteronuclear Co-II, Ni-II, Cu-II and Zn-II aqua complexes derived from dipicolinic acid. Inorg Chim Acta 2007;360:506–12.

60. Lever ABP. Inorg Electro Spect. Amsterdam, New York: Elsevier Pub Co. The Netherlands; 1968:420–1.

61. Ajibade PA, Kolawole GA, O’Brien P, et al. Cobalt(II) complexes of the antibiotic sulfadiazine, the X-ray single crystal structure of [Co(C10H9N4O2S)2(CH3OH)2]. Inorg Chim Acta 2006;359:3111–16.

62. Chandra S, Kumar R. Synthesis electrochemistry and spectral studies on cobalt(III) and manganese (II) complexes with 12-,14-,15-, and 18-membered N4,N 2O2,N 2O2S, N6 donor macrocyclic ligands. Synth React Inorg Met-Org Nano-Met Chem 2005;35:161–70.

63. Bayram E, Şentürk M, Kühreviolü Oi, Supuran CT. In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II. Bioorg Med Chem 2008;16:9101–5.

64. Lindskog S. Structure and mechanism of carbonic anhydrase. Pharmacol Ther 1997;74:1–20.